title: Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma.
abstract: OBJECTIVE
  To investigate the usefulness of branched-chain amino acids (BCAA) before transarterial chemoembolization (TACE) or radiofrequency ablation (RFA).
  
  
  METHODS
  We investigated the usefulness of pre-intervention with BCAAs by comparing patients treated with BCAAs at 12.45 g/d orally for at least 2 wk before TACE or RFA and those not receiving such pretreatment. A total of 270 patients with hepatocellular carcinoma complicated by cirrhosis were included in the study. Mean changes from baseline (Δ) in serum albumin (Alb), C-reactive protein (CRP), and transaminase levels, as well as peak body temperature were also determined and compared at days 2, 5, and 10 after the start of TACE or RFA.
  
  
  RESULTS
  In patients who underwent TACE or RFA, BCAA pre-intervention significantly suppressed the development of post- intervention hypoalbuminemia and reduced inflammatory reactions during the subsequent clinical course. After TACE, the ΔAlb peaked on day 2, remained constantly lower in BCAA-treated patients, compared to the control group, and was -0.13 ± 0.42 g/dL in BCAA-treated patients and -0.33 ± 0.51 g/dL in untreated patients on day 10. The ΔCRP was also significantly lower in BCAA-treated patients on days 2, 5 and 10 after TACE. Like the trends noted after TACE, a similar tendency was noted as to the ΔAlb and ΔCRP after RFA. The changes in serum Alb level were inversely correlated with CRP changes; therefore, a possible involvement of the anti-inflammatory effect of BCAAs was inferred as a factor contributory to the suppression of decrease in serum Alb level.
  
  
  CONCLUSIONS
  Pre-intervention with BCAAs may hasten the recovery of serum Alb level and mitigate post-operative complications in patients undergoing TACE or RFA.
authors.affiliation: Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Ishihara
authors.affiliation: Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
authors.forename: Motoh
authors.initials: M
authors.lastname: Iwasa
authors.affiliation: Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tanaka
authors.affiliation: Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kaito
authors.affiliation: Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
authors.forename: Jiro
authors.initials: J
authors.lastname: Ikoma
authors.affiliation: Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
authors.forename: Toshiya
authors.initials: T
authors.lastname: Shibata
authors.affiliation: Tomoaki Ishihara, Department of Gastroenterology and Hepatology, Yokkaichi Digestive Disease Center, Komono, Mie 510-1232, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Takei
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000597:Amino Acids, Branched-Chain / Q000008:administration & dosage*; D001833:Body Temperature Regulation / Q000187:drug effects; D002097:C-Reactive Protein / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation / Q000009:adverse effects; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D019587:Dietary Supplements; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D034141:Hypoalbuminemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D008297:Male; D012189:Retrospective Studies; D012709:Serum Albumin / Q000378:metabolism; D000075462:Serum Albumin, Human; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
chemical_list: C422455:ALB protein, human; D000597:Amino Acids, Branched-Chain; D012709:Serum Albumin; D002097:C-Reactive Protein; D000637:Transaminases; D000075462:Serum Albumin, Human
keywords: Branched-chain amino acids; Cirrhosis; Hepatocellular carcinoma; Hypoalbuminemia; Radiofrequency ablation; Transarterial chemoembolization